Algorae Pharmaceuticals Issues New Shares and Confirms Regulatory Compliance

The latest announcement is out from Living Cell Technologies ( (AU:1AI) ).

Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in a contemporaneous Appendix 2A lodgement, and has confirmed that these securities were issued without a prospectus under the Act’s disclosure exemptions. The company states it remains compliant with its financial reporting and continuous disclosure obligations and that no excluded information is required to be disclosed, indicating the new share issue is procedurally routine and not driven by undisclosed material developments.

This cleansing notice assures investors that Algorae has met all relevant Corporations Act requirements in connection with the latest share issuance. By confirming there is no additional undisclosed price-sensitive information, the company seeks to maintain transparency and regulatory confidence around its capital management activities while potentially broadening its shareholder base.

The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is an Australia-based biotechnology company listed on the ASX under the ticker 1AI. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of drug and healthcare-related technologies for domestic and potentially international markets.

YTD Price Performance: 21.43%

Average Trading Volume: 2,043,058

Technical Sentiment Signal: Buy

Current Market Cap: A$30.61M

For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.